DAVID RAMIN: Open Payments
NPI 1992893424 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,837 in 96 payments from 20 companies in 2025. Trend: 2023 $1,379 · 2024 $2,373 · 2025 $2,837
Food & beverage: $2,837
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 19 | $611 |
| Amgen Inc. | 12 | $489 |
| Gilead Sciences, Inc. | 6 | $246 |
| Novo Nordisk Inc | 10 | $228 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $195 |
| Axsome Therapeutics, Inc. | 4 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $116 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $114 |
| Kowa Pharmaceuticals America, Inc. | 5 | $96 |
| Lilly USA, LLC | 3 | $84 |
Products named: OTEZLA, Kerendia, Ozempic, BREZTRI, AIRSUPRA, FARXIGA, Auvelity, Yeztugo.
Industry payments across CA — which companies pay providers there.
